Development of PI3Kγ selective inhibitors: the strategies and application

被引:3
|
作者
Gu, Dong-Yan [1 ]
Zhang, Meng-Meng [2 ]
Li, Jia [2 ]
Zhou, Yu-Bo [2 ]
Sheng, Rong [1 ]
机构
[1] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Peoples R China
[2] Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, State Key Lab Drug Res, Shanghai 201203, Peoples R China
基金
中国国家自然科学基金;
关键词
PI3K; PI3K gamma inhibitors; isoform selectivity; drug development; rational drug design; PI3K INHIBITORS; SOLID TUMORS; INFLAMMATION; DISCOVERY; PI3K-DELTA; TARGETS; THERAPY; LESSONS; PATHWAY;
D O I
10.1038/s41401-023-01166-8
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The gamma isoform of Class I PI3Ks (PI3K gamma) is primarily found in leukocytes and is essential for the function of myeloid cells, as it regulates the migration, differentiation, and activation of myeloid-lineage immune cells. Thus, PI3K gamma has been identified as a promising drug target for the treatment of inflammation, autoimmune disease, and immuno-oncology. Due to the high incidence of serious adverse events (AEs) associated with PI3K inhibitors, in the development of PI3K gamma inhibitors, isoform selectivity was deemed crucial. In this review, an overview of the development of PI3K gamma selective inhibitors in the past years is provided. The isoform selectivity of related drugs was achieved by different strategies, including inducing a specificity pocket by a propeller-shape structure, targeting steric differences in the solvent channel, and modulating the conformation of the Asp-Phe-Gly DFG motif, which have been demonstrated feasible by several successful cases. The insights in this manuscript may provide a potential direction for rational drug design and accelerate the discovery of PI3K gamma selective inhibitors.
引用
收藏
页码:238 / 247
页数:10
相关论文
共 50 条
  • [1] Development of PI3Kγ selective inhibitors: the strategies and application
    Dong-yan Gu
    Meng-meng Zhang
    Jia Li
    Yu-bo Zhou
    Rong Sheng
    Acta Pharmacologica Sinica, 2024, 45 : 238 - 247
  • [2] Development of novel, selective and irreversible PI3Kδ inhibitors
    Dalton, Samuel
    Campos, Sebastien
    Bush, Jacob
    Thomas, Daniel
    Convery, Maire
    Murphy, John
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [3] Development of Scalable Syntheses of Selective PI3K inhibitors
    Huang, Qinhua
    Richardson, Paul F.
    Sach, Neal W.
    Zhu, Jinjiang
    Liu, Kevin K-C.
    Smith, Graham L.
    Bowles, Daniel M.
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2011, 15 (03) : 556 - 564
  • [4] Designing selective PI3K inhibitors
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2010, 9 : 105 - 105
  • [5] Designing selective PI3K inhibitors
    Crunkhorn, Sarah
    NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (02) : 105 - 105
  • [6] The development of inhibitors of PI3K and Akt
    Dennis, PA
    ANNALS OF ONCOLOGY, 2006, 17 : 24 - 24
  • [7] Clinical development of inhibitors of the PI3K
    Saura Manich, C.
    CANCER RESEARCH, 2019, 79 (04)
  • [8] PI3K inhibitors: review and new strategies
    Zhang, Mingzhen
    Jang, Hyunbum
    Nussinov, Ruth
    CHEMICAL SCIENCE, 2020, 11 (23) : 5855 - 5865
  • [9] Discovery of Potent and Selective PI3Kγ Inhibitors
    Drew, Samuel L.
    Thomas-Tran, Rhiannon
    Beatty, Joel W.
    Fournier, Jeremy
    Lawson, Kenneth, V
    Miles, Dillon H.
    Mata, Guillaume
    Sharif, Ehesan U.
    Yan, Xuelei
    Mailyan, Artur K.
    Ginn, Elaine
    Chen, Jie
    Wong, Kent
    Soni, Divyank
    Dhanota, Puja
    Chen, Pei-Yu
    Shaqfeh, Stefan G.
    Meleza, Cesar
    Pham, Amber T.
    Chen, Ada
    Zhao, Xiaoning
    Banuelos, Jesus
    Jin, Lixia
    Schindler, Ulrike
    Walters, Matthew J.
    Young, Stephen W.
    Walker, Nigel P.
    Leleti, Manmohan Reddy
    Powers, Jay P.
    Jeffrey, Jenna L.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (19) : 11235 - 11257
  • [10] Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors
    Ma, Chen-Chen
    Zhang, Cheng-Mei
    Tang, Long-Qian
    Liu, Zhao-Peng
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 151 : 9 - 17